Proud to partner w/Life Science Cares to assemble 500+ snack packs & encouraging notes for local youth w/Youth Enrichment Services reflecting our value of service value & commitment to the wellbeing of our local community & those living w/ #depression, #anxiety & other #neuropsychiatric disorders.
Celebrating 2 years! Big clinical milestones this year: initiation of our Ph2b BUOY‑1 trial of GlyphAllo in MDD & positive proof-of-concept Ph1 topline data for GlyphAgo. Proud of our progress & what’s ahead as we make a difference for those struggling w/ #depression & #anxiety.
Positive Ph1 proof‑of‑concept topline results for GlyphAgo: 10x lower PK variability & 6.8x increase in bioavailability–exceeding our 2x target projected to mitigate liver exposure, a limitation that previously held back agomelatine's clinical use: bit.ly/3PBOkWV
New paper in Science Translational Medicine features GlyphAllo as first triglyceride-mimetic prodrug to achieve therapeutically relevant drug levels in humans & further validates Glyph platform to effectively enable oral dosing.
Paper: tinyurl.com/2mff276w
Release: tinyurl.com/5hdenetm
Seaport & Monash awarded up to $15M from ARPA‑H to advance GlyphCele™, supporting broader potential of Glyph platform to address diseases linked to gut lymphatic dysfunction (metabolic disease & pancreatic cancer) to reach patients beyond #CNS bit.ly/3MDnSLq
Our team presented new meta-analysis at #ISCTM showing that more frequent clinician‑administered assessments have a strong association with magnitude of placebo response in #GAD trials – consistent with findings from our #MDD meta‑analysis. bit.ly/4ru1EL1
We’re looking forward to our participation in three upcoming investor conferences in February & March: Leerink Partners Global Healthcare Conference, Oppenheimer 36th Annual Healthcare Life Sciences Conference, & Stifel 2026 Virtual CNS Forum. More here: bit.ly/4s1RvoF
Co‑founder & Board Chair Dr Steve Paul joined BioCentury's podcast to discuss the past, present & future of neuropsychiatric drug development – from the depression space to potential of psychedelics - & what we’re building at Seaport w/our Glyph platform: bit.ly/4r2gRCy
Our Seaport team started the year w/a gathering to celebrate the holidays & reflect on our progress last year. It was great to connect as a team & we're excited to carry this energy through 2026 as we continue our mission to serve those impacted by #neuropsychiatric conditions.
Co-founder & CEO @daphnezohar.bsky.social presented at #JPM26 sharing our recent progress & path forward as we tackle some of the biggest medical problems our population is facing today. Co-founders Steve Paul (Chair) & Michael Chen (CSO) joined for Q&A. #depression #anxiety #neuropsychiatry
Our Co-founder & CEO, @daphnezohar.bsky.social, will present at #JPM26 on Jan. 12 at 9:30AM PT. She’ll be joined by Steve Paul, M.D., Co-founder & Chair & Michael Chen, Ph.D., Co-founder & CSO, during the Q&A portion of the presentation. bit.ly/3NsW6kt
This year, we've made meaningful progress at Seaport from clinical milestones w/ the Ph2b BUOY‑1 study of GlyphAllo™ in #MDD (w/ or w/o anxious distress) & a Ph1 study of GlyphAgo™ for treatment of #GAD to moments together, made possible by our incredible team. #HappyHolidays!
Today at 10AM ET our CFO, Lauren White, & CSO, Michael Chen, PhD, will present at the RBC Capital Markets Healthcare Private Company Conference. Members of our team will also participate in 1x1 meetings.
Tune in: bit.ly/4a5zsYR
Replays: bit.ly/3MokeEE
#AES25: Data further validate Glyph’s ability to enhance oral bioavailability & expand therapeutic reach w/ successful application of Glyph to another class of clinically validated molecules previously held back by limitations Glyph’s designed to solve. bit.ly/44K0BwW
Members of our management team will present at the 2025 RBC Capital Markets Healthcare Private Company Conference on Dec. 11 at 10AM ET & will participate in 1x1 meetings at the conference.
Press release: bit.ly/3XTj7PT
Live & archived webcast: seaporttx.com/news-papers/
Team members joined @afspnational.bsky.social “Out of the Darkness” walk in Boston to raise awareness for suicide prevention. Our CMO, Tony Loebel, serves on AFSP's board, aligning w/ our mission to serve those w/ #mentalhealth conditions like #depression & #anxiety. Hear more from Tony!
Our CEO @daphnezohar joined the Making Medicine podcast to talk biotech, policy, & Seaport’s mission. Her take on price controls? The real impact would fall on patients, who are at the center of our work at Seaport. Hear her response in the full episode: www.youtube.com/watch?v=ICsz...
#HappyThanksgiving! Ahead of the holiday, we assembled care packages for Rosie's Place - a women's shelter in Boston - & enjoyed time together at a holiday lunch. Giving back reminds us that we're here to serve those living w/ #mentalhealth conditions like #depression & #anxiety.
Today Co-Founder & Board Chair Dr. Steve Paul joins Technology Innovation Studio’s Breakthrough Biotech Builders fireside chat on his role in the dev of CNS blockbusters Zyprexa®, Cymbalta® and Cobenfy™ (KarXT) which originated at PureTech (founded/led by @daphnezohar.bsky.social) luma.com/5rfgvqfd
Thanks to the NEVYs for nominating us for the Powerhouse Healthcare Company of the Year at the #NEVYs25Awards! Great progress this year w/ the launch of two clinical trials & we look forward to making a difference for those w/ #neuropsychiatric conditions: bit.ly/nevy25
Tune in today at 10:00AM EST as our CFO, Lauren White, & CSO, Michael Chen, present at the Stifel 2025 Healthcare Conference. The team will also participate in 1x1 meetings while at the conference.
Tune in: bit.ly/4oNTUBA
Replay available here: bit.ly/43Nvu33
Members of our management team will present at the Stifel 2025 Healthcare Conference on November 11 at 10:00AM ET. The team will also participate in 1x1 meetings during the conference.
Press release: bit.ly/49x28cP
Live & archived webcast here: seaporttx.com/news-papers/
Happy Halloween! We had so much fun celebrating together w/ themed team costumes & plenty of laughs. These gatherings remind us how connection energizes our shared commitment to developing new medicines for people living w/ #neuropsychiatric conditions like #depression & #anxiety.
Co-Founder & CEO, @daphnezohar.bsky.social joined an all-women Rare & Neuro Diseases panel at #USAIC25 (watch: bit.ly/3LcJkWg) & gave a shoutout to the Biotech CEO Sisterhood in her opening remarks (view: bit.ly/3X1WPKY).
Join us at #USAIC26: bit.ly/4oEvmei
“We Own It” is a core value of ours & captures our entrepreneurial spirit. Co-Founder & CEO, @daphnezohar.bsky.social, shows us how it's done. Named a Goldman Sachs Most Exceptional Entrepreneur, she inspires us to push boundaries so we can best serve those with #neuropsychiatric conditions.
Board member, Denice Torres, shared her expertise on happiness, a core value & key to our work. We aim to increase happiness worldwide & develop novel medicines for #neuropsychiatric conditions. This #WorldMentalHealthDay, we’re reminded that happiness & mental health are linked.
Members of our exec team joined Fierce Biotech’s #Fierce15 awards to celebrate our recognition, honoring our team's work developing new medicines for #depression & #anxiety. It's also a reflection of the strong momentum & growth since our launch last year. bit.ly/3VSOQQ7
We convened top neuropsych experts, sell-side analysts, investors, & biopharma leaders for a unique roundtable discussion on the opportunities & excitement in #neuropsychiatry & what’s next as #MentalHealth conditions continue to impact millions globally. See below for some takeaways
Tune in today at 11:45 AM ET to hear our CFO Lauren White & COO Eric Green present at the Oppenheimer Private Life Sciences Company Showcase. Live webcast: bit.ly/4nllNke & replay available on our website: seaporttx.com/news-papers/
We’re a Fierce Biotech Fierce 15 winner! Our Glyph platform, proven team, & focus on validated mechanisms put us among the most “innovative & visionary” companies as we advance clinical programs aiming to deliver new medicines for #depression & #anxiety. bit.ly/4msojnm
